Cytochrome P450 lanosterol 14-a a demethylase (CYP51), participated in keeping serum cholesterol homeostasis, is a key enzyme to synthesize cholesterol from lanosterol. Here we focused on investigating the mechanism of CYP51 in modulating serum cholesterol levels in mouse through RNA interference (RNAi). Mice fed on normal or high fat high cholesterol (HFHC) diets were individually treated with small interference RNA (siRNA) of CYP51 gene by tail vein injection. The results showed that administrated single dose of 10 m mg CYP51-siRNAs for 48 h resulted in significantly depletion of CYP51 mRNA in liver of mice fed on normal diet (from 40 to 60%, pϽ0.05). CYP51-siRNAs exerted the inhibition in a dose dependent manner (from 26% in 5 m mg to 40% in 20 m mg, pϽ0.05) and most inhibitive effect from day 3 to day 6 (over 50%, pϽ0.05) after the treatment. Six days after administration of 30 m mg CYP51-siRNAs (20 m mg on day 0 and 10 m mg on day 3), CYP51 mRNA (normal: 50%; HFHC: 70%, pϽ0.05) and protein levels (normal and HFHC: over 40%, pϽ0.05) were significantly knocked down in mice liver. Interestingly, low-density lipoprotein receptor (LDLR) expression was significantly elevated compared with controls in hepatic cells after CYP51-siRNAs (mRNA: about 2 times; protein: about 1.6 times, pϽ0.05). As a consequence, about 50% of sera low-density lipoprotein cholesterol (LDL-ch) were significantly reduced (pϽ0.05). The effect on LDLR increase and LDL-ch reduction lasted 8 d after a single 20 m mg CYP51-siRNAs injection. In addition, CYP51-siRNAs could not cause any fatty liver compared with Buffer-group and did not interfere with mice ovulation. In conclusion, these data demonstrated that CYP51-siRNAs silenced CYP51 in mouse liver and down-regulated plasma LDL-ch levels. The potential mechanism of LDL-ch reduction may be related to up-regulated LDLR expression of hepatic cells. It indicated that there was a cholesterol levels linkmodulation system between cholesterol synthetic pathway through CYP51 and cholesterol transport pathway through LDLR in vivo. Fig. 2. The Effect of siRNA Treatment on Mice Body Weights (A) Appearance of mice fed on normal chow diet for 14 d; (B) Appearance of mice fed on high fat and high cholesterol (HFHC) chow diet for 14 d; (C, D) CYP51 protein expression was measured in liver tissues of mice fed on normal diet and HFHC diet by Western blot analysis.
Hypercholesterolemia is a proven major risk factor in coronary artery disease (CAD), which is associated with endothelial dysfunction and atherosclerotic lesion formation. Down-modulating circular low-density lipoprotein cholesterol (LDL-ch) levels become a predominant clinical strategy for the control of CAD and is achieved by modification of dietary cholesterol and/or inhibition of endogenous cholesterol synthesis with pharmacological therapies. 1) Currently, statins are the most widely used drugs for hypercholesterolemia because they specifically inhibit the activity of the first key enzyme of cholesterol metabolism, 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase (HMGCR). [2] [3] [4] However, as much as 8% patients under statins treatment alone do not achieve the goal of down-regulated LDL-ch levels well and remain at significant risk for CAD. 5, 6) Moreover, animal models (rat, mouse and rabbit) and human medicine have provided some evidences that the deleterious effect of statins on female reproduction. [7] [8] [9] [10] Therefore, it is necessary to explore alternative therapeutic approaches.
Previous studies indicate that lanosterol demethylation is another rate-limiting step in cholesterol synthesis. 11) Therefore, cytochrome P450 lanosterol 14-a demethylase (CYP51), which is a key cholesterol-synthesized enzyme for catalyzing lanosterol to 4,4-dimethylsterols, 12) is considered to become a potential target gene down-regulating cholesterol levels in vivo. The CYP51 nonspecific inhibitors, such as azalanstat (RS-21607), 13) ketoconazole 12) and its analogues, 14) can reduce circular cholesterol levels by inhibiting cholesterol-synthesized enzymes activities. However, just because of their nonspecific characters, it is difficult to dissect the mechanism of down-regulating circular cholesterol levels with these drugs. It is still obscure whether CYP51 could be an ideal therapeutic target for hypercholesterolemia.
Recently developed RNA interference (RNAi) technique, an evolutionarily conserved surveillance mechanism by sequence-specific silencing of homologous genes, brings a considerable therapeutic strategy to knockdown diseasecausing genes that are not amenable to conventional therapeutics. [15] [16] [17] Respectively administration of chemically modified small interference RNA (siRNA) 18, 19) and anti-sense oligonucleotide 6) into mice, non-primates and human result in silencing endogenous gene-encoded apolipoprotein B (apoB), which consequently decrease plasma apoB protein and sera cholesterol levels. These observations prompted us, in the current paper, to directly investigate the competence and potential mechanism of modulating circular cholesterol levels through silencing CYP51 with RNAi in vivo. Since systemic CYP51-siRNA delivery might affect oocyte meiotic resumption in ovary, the present research was performed in models of female mice fed on high fat high cholesterol (HFHC) diets in order to evaluate possible adverse effect of CYP51-siRNA on ovulation.
MATERIALS AND METHODS
Designing, in Vitro Transcription and Screening of CYP51 Specific siRNAs CYP51-siRNAs were designed with software of Ambion (Austin, TX, U.S.A.) and modified under the suggestions of Reynolds et al. 20) The sequences of CYP51-siRNAs were shown in Table 1 . CYP51-siRNAs were synthesized by in vitro transcription method according to the manufacturer's protocol (Jingmei Biotech Co., Ltd., Beijing, P. R. China). In brief, DNA templates for synthesizing CYP51-siRNAs were conjugated with T7 polymerase promoter at each single strand 5Ј end of the templates. 5 mM of sense and anti-sense DNA templates were respectively put into the same transcription buffer tube in 50 mM MgCl 2 , 25 mM NTPs, 20 U/ml T7 polymerase (Jingmei Biotech Co.) supplemented with 40 U/ml RNasin (TAKARA Biotechnology (Dalian) Co., Ltd., Dalian, China) and kept in 37°C for over 6 h. Then, adding 5 U/ml of RNase-free DNase I (Jingmei Biotech Co.) and 4 U/ml of RNase T1 (Jingmei Biotech Co.) into the tube and kept in 37°C for 2 h to digest DNA templates and single strand RNAs. The double strand siRNAs were extracted through TriZol reagent (Invitrogen Corporation, Carlsbad, California, U.S.A.) and then washed in 75% ethanol, dissolved in water. After quantification with DU640 spectrophotometer (Beckman Coulter, Inc., Palo Alto, Calif., U.S.A.), the products were confirmed by electrophoresis in a 4% agarose gel and stored in water at Ϫ80°C.
To determine the efficacy of designed four CYP51-siRNAs, they were separately injected into mice body through hydrodynamic tail vein injection according to Lewis et al. 21) The injection volume was 0.1 ml/g weight. Before injection, siRNA solutions were warmed to 37°C and sucked into 3 ml syringe fitted with 27 gauge, 0.5 inch long syringe needles. Maximum delivery was attained by quick injection at a constant speed, delivering the entire contents of the syringe in 7-10 s. Animals were warded for 5-10 min to recover from anesthesia. Control animals were injected with sterile RNase-free delivery buffer containing 147 mM NaCl, 4 mM KCl and 1.13 mM CaCl 2 (Ringer's solution).
Animal Preparation Six weeks old female Kunming White mice were housed under controlled temperature (22-26°C) and light (14 h light; 10 h dark) and fed ad libitum. The experiments were carried out in accordance with the principles and guidelines for the use of laboratory animals and approved by science research animal committee of China Agricultural University.
Semi-quantitative and Real Time PCR Detection of CYP51 and LDLR mRNA Mice were killed after sera collection and the liver tissues were stored in liquid nitrogen. The total RNA from mice liver were isolated with TriZol reagent according to the manufacturer's protocol and washed in 75% ethanol and then dissolved in water. After quantification with DU640 spectrophotometer (Beckman), the products were confirmed by electrophoresis in a 1% agarose gel and then stored in water at Ϫ80°C. The unique PCR primers specific for the genes designed using Oligo 6.0 software and sequence data from the National Center for Biotechnology In-formation database ( Table 1) . First-strand cDNA was created by RT (Promega Reverse Transcription System, U.S.A.) from 1 mg total RNA. The RT proceeded for 1 h at 42°C.
RT-PCR and real-time PCR were performed for quantifying CYP51 and low-density lipoprotein receptor (LDLR) mRNA expression in hepatic tissues. The primer sequences for CYP51, b-actin and LDLR were shown in Table 2 . PCR cycle conditions for genes were: initially denatured at 94°C for 5 min, followed by 26 cycles of 94°C for 20 s, 52°C for 20 s, and 72°C for 20 s, finished with a final extension at 72°C for 10 min.
For semi-quantitative PCR, b-actin was used as the internal standard. The PCR was performed with Bio-Rad (Bio-Rad Laboratories, Inc., Hercules, California, U.S.A.) machine and the products were subjected to electrophoresis in a 3% agarose gel, and the signals were quantified by AlphaImager 2200 analysis software (Alpha Innotech Corp., San Leandro, CA, U.S.A.).
For Real-time PCR, products were amplified in reactions containing 10ϫ SYBR Green I PCR buffer, 25 mM MgCl 2 , 12.5 mM dNTPs, 10 mM primers, 1 U/ml AmpErase UNG (Applied Biosystems, CA, U.S.A.) and 5 U/ml AmpliTaq Gold (Hoffmann-Lar., Roche Ltd., Greezachestrasse, Switzerland). The PCR was performed with ABI prime 7900HT according to the manufacturer's protocol. The data were quantified using the ABI 7900HT SDS 2.2 analysis software. A standard curve for the CYP51 plasmid was created and the standard error was Ͻ0.005. The results were expressed initially as the number of target molecules per 1 ml cDNA. To standardize the results for variability in RNA and cDNA quantity and quality, we quantified the total number of bactin transcripts in each sample as an internal control. Normalized levels of the CYP51 and LDLR transcripts were cal- Designed primers of CYP51, b-actin and LDL-R gene for PCR were shown. The cDNAs of these genes were taken from Genebank (gi9910171), (gi6671508) and (gi31419349), respectively. Small interference RNA sequences. Small interference RNAs were acquired by In Vitro Transcription T7 kit according to producer's protocol (Jingmei Biotech Co., Ltd., Beijing, China). The sequence for CYP51 was taken from Genebank (gi9910171). culated as the ratio of CYP51/b-actin and LDLR/b-actin. We confirmed the RT-PCR products by 3% agarose gel electrophoresis.
Western Blot Detection of CYP51 Expression Total proteins of all mice liver were extracted in MEM-R according to manufacturer's protocol (Perice company, U.S.A.) and then measured by BCA procedure (Cellchipbj Biotechnology Co., Ltd., Beijing, China) to normalize the quantity of sum proteins. Each sample was heated to 100°C for 5 min. After cooling down on ice for 20 min and centrifuging at 12000 rpm for 5 min, samples were frozen at Ϫ80°C until use. The 25 mg protein complexes of each sample were loaded on SDS-PAGE. Samples were separated by SDS-PAGE with a 4% stacking gel and a 10% separating gel for 60 min at 160 V and transferred onto a piece of Protran nitrocellulose membrane with electrophoresis (Schleicher & Schuell, Dassel, Germany) for 2 h at 200 mA using a Trans-Blot apparatus (Bio-Rad Laboratories, Hercules, CA, U.S.A.). After blocking for 1 h with 5% nonfat dry milk in 20 mM Tris and 137 mM NaCl (TBS, pH 7.6), the membrane was incubated overnight at 4°C with rabbit anti-CYP51 (55 kDa) antibodies with 1/400 dilution (gift from Dr. Anne Grete), goat anti-LDL receptor (160 kDa) antibody with 1/200 dilution (Santa Cruz company, U.S.A.) and mouse anti-GAPDH (37 kDa) antibodies with 1/8000 dilution (Ambion Company, U.S.A.). After three washes of 5 min each in TBS containing 0.1% Tween-20, the membrane was incubated for 1 h at room temperature with horse radish peroxidase-conjugated goat anti-rabbit, rabbit anti-goat and goat anti-mouse IgG diluted 1/5000 in TBST. After three washes in TBST, the membrane was visualized using the enhanced chemiluminescence detection system (Amersham, Arlington Heights, IL, U.S.A.).
Serum Cholesterol and LDL-ch Measurement
The serum cholesterol and LDL-ch levels of all mice were measured by technicon RA-1000 auto analysis machine (Bayer Corporation, U.S.A.). The analysis reagents were purchased from Zhongsheng Beikong Bio-technology and Science Inc. (Beijing, China).
Histological Evaluation of Fat Liver Liver fat accumulation after CYP51-siRNA treatment was evaluated by histological observation. Mice liver tissues were infiltrated by 10% sucrose solution. Ten micrometer frozen liver sections were cut by a freezing microtome. Then the sections were dyed with SudanIII and counterstained with hematoxylin.
Cumulus-Oocyte Complex (COC) Isolation after Ovulation Mice were killed by cervical dislocation and oviducts were immediately recovered and transferred to PBS buffer. The oviducts were torn with sterile needles. All COCs were collected and digested 3 min with hyaluronidase at 37°C. Oocytes were denuded mechanically and oocyte number was recorded. The experiments were repeated at least three times and the values were given as the meanϮS.E.M. The columns represented average number of oocytes with each mouse.
Experimental Designing 1. Preliminary Investigation of the RNAi Effect on CYP51 Expression in Vivo: Four CYP51-siRNAs with 10 mg dose were injected into mice body, respectively. The efficiency of CYP51-siRNAs was justified through RT-PCR and Real-time PCR methods. To determine the suitable dose of CYP51-siRNA effect in vivo, CYP51-siRNAs were injected into mouse tail vein with 5, 10 and 20 mg dose and the CYP51 protein expression in liver and lung were investigated at 48 h after injection. Moreover, CYP51 protein levels in liver of mice fed on normal diet were measured at times of day 0, 1, 3, 6, 10 and 14 after treatment with a single 20 mg CYP51-siRNAs.
2. The Effect of CYP51-siRNAs on Mouse Body Weight: Kunming White mice of about 20 g were fed on normal diet for 7 d. Then, mice with similar body weights were randomly divided into two models and fed on normal diet or high fat high cholesterol diet (normal diet supplemented with 0.2% bile acid, 10% lard, 10% egg yolk powder and 1% cholesterol) for another 2 weeks before RNAi experiments. Mice in each model were injected with 20 mg (day 0) plus 10 mg (day 3) of CYP51-siRNAs through tail vein and fed for 6 d. For the positive control, a HMGCR inhibitor, simvastatin (Merck Sharp & Dohme Ltd., U.K.) was given to the mice orally at 5 mg/kg/d for 6 d. Control animals were injected with buffer (Ringer's solution) or CYP-mismatch. Then, mice body weights were measured. At least five mice were used in individual treatments of both models.
3. The RNAi Effect on CYP51 and LDLR Expression in Liver: Mice in each model were treated with above protocol. Both CYP51 and LDLR mRNA levels in hepatic tissues were measured by RT-PCR and Real time PCR, respectively. CYP51 or LDLR protein expression was measured by Western blot analysis.
4. The RNAi Effect on Regulating Circular Cholesterol and LDL-ch Levels: Mice of similar weights in each model were treated with above protocol. After mice of both models were fasted for 4 h, blood samples were collected and the sera cholesterol and LDL-ch levels of all treatments were measured for investigating the action of CYP51-siRNAs on circular cholesterol and LDL-ch levels. Sera of at least 3 mice per group were measured in each experiment. Mice blood samples of each treatment were collected from 10-12 mice. The experiments were repeated for three times independently.
5. Time Kinetics Effect of the siRNA Treatment for LDL-ch and LDLR: HFHC mice liver tissues and blood samples were collected at day 3, 8 and 10 after a single injection with 20 mg CYP51-siRNAs. Sera cholesterol or LDL-ch levels and LDLR protein expression were measured respectively for investigate time kinetics effects of the siRNA treatment.
6. Evaluation of Fat Accumulation in Liver after CYP51-RNAi: HFHC mice liver tissues were collected at day 8 after a single injection with 20 mg CYP51-siRNAs. The fat content of murine livers was evaluated with SudanIII dye. Positive fatty hepatocytes show red. The sections were evaluated from 6 mice of each treatment.
7. Evaluation of Possible Adverse Effect on Ovulation after CYP51-RNAi: After CYP51-siRNAs treatment (20 mg each HFHC mouse), each mouse was primed 5 IU of equine chorionic gonadotropin (eCG) and after 48 h, 5 IU of human chorionic gonadotropin (hCG) was primed. After 12-14 h, expanded COCs were recovered from oviducts and oocyte number was recorded. Oocyte number was counted from 12 mice of each treatment.
Statistics The data of mice body weight, serum cholesterol and LDL-ch levels, and the mRNA and protein levels of CYP51 or LDLR expression were statistically analyzed by ANOVA using Sigma plot 9.01 software (SISTAT soft-ware, Inc., Chicago, Illinois, U.S.A.). When a significant F ratio was defined by ANOVA, groups were compared using Holm-Sidak method test. Differences were considered significant at pϽ0.05. Each experiment was repeated for three times at least.
RESULTS

CYP51-siRNA Screening in Liver
Mice hepatic tissues were collected and CYP51 mRNA levels were quantified at 48 h after tail vein injection of CYP51-siRNAs. The results showed that the RNAi efficiencies were different among four CYP51-siRNAs with 10 mg dose by both semi-quantitative PCR and Real-time PCR analysis (Figs. 1A, B ). In brief, CYP-1 and CYP-4 siRNAs significantly degraded CYP51 mRNA, which cut down more than 60% and 43% of CYP51 mRNA compared with Buffer-group, respectively (pϽ0.05). CYP-3 siRNAs also knocked down 40% of CYP51 mRNA (pϾ0.05), whereas CYP-mismatched siRNAs had hardly any effects (2%) on silencing CYP51 mRNA (pϾ0.05). As a result, CYP-1 siRNA was selected as the positive siRNAs and CYP-mismatched siRNA (CYP-mis) was chosen as the negative one for follow studies.
For testing the suitable dose and time of CYP51-siRNA effect in vivo, we investigated dose and time kinetics in liver of mice fed on normal diet after siRNA treatment. The results showed that the CYP51 expression decreased gradually along with CYP-1 dose increased and 20 mg CYP-1 got the highest RNAi effect (about 40%, pϽ0.05) (Figs. 1C, D) . When 20 mg CYP-1 were individually injected into mice bodies, the CYP51 knockdown also showed to be time dependent in liver during 14 d. As was shown, the highest inhibiting effect (over 50%, pϽ0.05) showed up from day 3 to day 6 (Figs. 1E, F). Furthermore, we did not observe significant change of CYP51 expression in lung after injection of CYP-1 from 5 to 20 mg (Figs. 1G, H) . In sum, CYP51-siRNAs knocked down CYP51 protein expression of mouse liver time-and dose-dependently. Groups with asterisk on the columns were significantly different compared with Buffer-group (pϽ0.05). The levels of CYP51 mRNA were normalized according to b-actin to evaluate the relative expression of the target. The experiment was performed at least three times with similar results. (C, D) Forty eight hours after 5, 10 and 20 mg of CYP51-siRNAs were individually injected into mice, CYP51 protein expression levels in mice liver tissues were measured by Western blot analysis. (E, F) CYP51 protein levels in mice liver were measured at times of day 0, 1, 3, 6, 10 and 14 after treated with a single 20 mg CYP51-siRNAs by Western blot analysis. (G, H) Forty eight hours after 5, 10 and 20 mg of CYP51-siRNAs were individually injected into mice, CYP51 protein expression levels in mice lung tissues were measured by Western blot analysis. In (D), (F) and (H), the densitometric data of CYP51 were normalized according to GAPDH to evaluate the relative expression of the target. Groups with asterisk on the columns were significantly different compared with Buffer-group or day 0-group (pϽ0.05). The experiment was performed at least three times with similar results.
The Effect of the siRNA Treatment on Mice Body
Weight After fed on either normal or HFHC diet for two weeks before RNAi treatment, mice body weights were significantly risen compared with day 0 and HFHC mice weights were significantly higher than normal mice (Figs. 2A, B, E). After RNAi experiments, the body weights of mice fed on normal diet, but not HFHC, increased significantly for the 6 d-treatment period (pϽ0.05) ( Fig. 2E) . The data showed that neither CYP-1 nor simvastatin contributed to lower mouse body weight during short time treatments (totally 6 d). In addition, before RNAi treatment, CYP51 protein levels in liver of HFHC mice were lower than normal mice (over 40%, pϽ0.05, Figs. 2C, D) .
The siRNAs Inhibited CYP51 Expression and Up-Regulated LDLR Levels in Liver
To measure CYP51 and LDLR levels after 6 d siRNA treatment in both models, mice liver tissues were collected and the levels of target genes expression were measured through RT-PCR, Real time PCR and Western blot analysis. The results showed that in normal mice, CYP51 mRNA and protein levels were significantly knocked down (nearly 50%) (pϽ0.05) by CYP-1, on the contrary, simvastatin significantly elevated CYP51 mRNAs (about 2-times) (pϽ0.01) and protein (about 1.6-times) (pϽ 0.05) (Figs. 3A-D) . In HFHC mice, nearly 70% mRNA and 40% protein levels of CYP51 expression were degraded by CYP-1 (pϽ0.05), but in contrast to normal mice, simvastatin 
CYP51-RNAi Down-Regulated Serum LDL-ch Levels of Mice
Sera cholesterol and LDL-ch levels of HFHC mice were significantly higher than normal mice as was shown in Figs. 5A, B . The RNAi effect on mice sera cholesterol and LDL-ch levels were measured by technicon RA-1000 auto analysis machine for 6 d after RNAi in both models. The results showed that neither CYP-1 nor simvastatin significantly influenced sera cholesterol levels (Fig. 5A) (pϾ0.05) . Contrary to that, they both significantly reduced LDL-ch levels in normal and HFHC mice in similar to the effect of simvastatin, which the LDL-ch levels were both reduced about 50% compared with controls ( Fig. 5B) (pϽ0.05) . Figs. 6A, B , LDLR protein expression in liver of HFHC mice were significantly up-regulated 1.6-times at day 3 and 1.4-times at day 8 compared with Buffer group after CYP-1 treatment (pϽ0.05). At day 10, LDLR levels of CYP-1 group were almost equal to Buffer group. In similar to LDLR expression pattern, sera LDL-ch levels were significantly down-regulated about 40% at day 3 and 20% at day 8 compared with Buffer group after CYP-1 injection (pϽ0.05). At day 10, sera LDL-ch levels of CYP-1 group recovered the levels of Buffer group (Fig. 6D) . Sera cholesterol levels of CYP-1 group decreased in a certain extent at day 3 and day 8, but it was not significant (pϾ0.05) (Fig. 6C) .
Time Kinetics Effect of CYP51-RNAi in LDLR Expression and LDL Levels As shown in
CYP51-siRNA Treatment Did Not Cause a Fatty Liver
Because the effect of CYP-1 could up-regulate LDLR expression in liver, it is necessary to investigate whether mice liver accumulates excess amount of cholesterol to become a fatty liver. The extension of fatty hepatocytes was estimated with histological observation by SudanIII dye. The results showed that the siRNA treatment did not cause any fatty hepatocytes increasing compared with Buffer group (Figs.
7A-C).
CYP51-siRNA Treatment Did Not Affect Mice Ovulation In order to investigate whether CYP51-siRNAs interfered with mouse ovulation, CYP51-siRNAs were introduced into mice through tail vein injection. The results showed that CYP51-RNAi had no significant effect in oocyte number of mice ovulation (Fig. 8 ).
DISCUSSION
Our present study gave the evaluation of ability on CYP51alleviated hypercholesterolemia and indicated potential mechanism of CYP51-modulated sera LDL-ch levels by directly inhibiting the expression of CYP51 gene with RNAi. The data showed that 40 to 60% of CYP51 mRNA levels were significantly knocked down in mice liver 48 h after 10 mg 
. RNAi Action on CYP51 and LDL Receptor (LDLR) Expression in Normal Mice Liver
Six days after CYP-1 treatment on normal mice, liver tissues were collected to extracted total RNA and protein. CYP51 and LDLR mRNA levels were measured by RT-PCR (A) and real time PCR (B). In (B), groups with no identical letters on the same colored columns were significantly different (pϽ0.05). The levels of CYP51 and LDLR mRNA were normalized according to b-actin to evaluate the relative expression of the targets. The experiment was performed at least three times with similar results. (C, D) CYP51 protein expression was measured by Western blot analysis. (E, F) LDLR protein expression was measured by Western blot analysis. In (D) and (F), the densitometric data of CYP51 and LDLR were normalized according to GAPDH to evaluate the relative expression of the targets. Groups with no identical letters or asterisk on the columns were significantly different (pϽ0.05). The experiment was performed at least three times with similar results. A, B, a, b, c: expressed the meaning that groups with different letters on the columns were significantly different (pϽ0.05).
Fig. 4. RNAi Action on CYP51 and LDLR Expression in HFHC Mice Liver
Six days after CYP-1 treatment on HFHC mice, liver tissues were collected to extracted total RNA and protein. CYP51 and LDLR mRNA levels were measured by RT-PCR (A) and real time PCR (B). In (B), groups with no identical letters on the same colored columns were significantly different (pϽ0.05). The levels of CYP51 and LDLR mRNA were normalized according to b-actin to evaluate the relative expression of the targets. The experiment was performed at least three times with similar results. (C, D) CYP51 protein expression was measured by Western blot analysis. (E, F) LDLR protein expression was measured by Western blot analysis. In (D) and (F), the densitometric data of CYP51 and LDLR were normalized according to GAPDH to evaluate the relative expression of the target. Groups with no identical letters on the columns were significantly different (pϽ0.05). The experiment was performed at least three times with similar results. A, B, a, b, c, d: expressed the meaning that groups with different letters on the columns were significantly different (pϽ0.05).
Fig. 5. RNAi Effect on Modulating Serum Cholesterol and LDL-ch Levels
Six days after the CYP-1 treatment on normal and HFHC mice, serum cholesterol and LDL-ch levels were measured by technicon RA-1000 auto analysis machine. (A) Serum cholesterol levels change after the siRNA treatment; (B) serum LDL levels change after the siRNA treatment. Normal (black columns) and HFHC (gray columns) groups with no identical letters on the columns were significantly different (pϽ0.05). The experiment was performed at least three times with similar results. Blood samples were collected from 10-12 mice per treatment. CYP51-siRNAs injection. CYP51-siRNAs exerted the inhibition in a dose dependent manner from 5 to 20 mg and most inhibitive effect from day 3 to day 6 after 20 mg CYP51-siRNAs treatment. CYP51 mRNA (about 50%) and protein (about 40%) levels in mice liver were respectively knocked down in either normal or HFHC mice at day 6 after 30 mg CYP51-siRNAs treatment (20 mg on day 0 and 10 mg on day 3). LDLR expression were significantly elevated compared with controls in hepatic cells after the siRNAs treatment in both models (mRNA: about 2 times; protein: about 1.6 times). Consequently, mice sera LDL-ch levels were significantly reduced by half through CYP51 knockdown. The reduction of CYP51 expression after RNAi prolonged almost 1 week till it recovered previous level. In accordance, the increase in LDL receptor expression in hepatic cells and serum LDL level reduction lasted as long as 8 d after a single tail vein injection of 20 mg CYP51-siRNAs.
Physiologically, LDL-ch is the main carrier responsible for transport and depletion of cholesterol in vivo. The regulation of the intracellular cholesterol pool also involved in modulat- ing the transcription of hepatic LDLR in vivo. 22) Because statins can stimulate LDLR expression to promote depletion of circular LDL-ch, 3) we wonder if CYP51 also involved in modulating circular cholesterol homeostasis through LDLR pathway. The data showed that LDLR levels in mice hepatic tissues were significantly increased about 2-times of mRNA and 1.6-times of protein after CYP51-RNAi in either normal or HFHC mice models. The effect prolonged 8 d after a single CYP51-siRNAs injection. It suggested that CYP51-siRNAs improved LDLR expression in hepatic cells through decrease of intra cellular synthesized cholesterol. As had been demonstrated, inhibition of cholesterol biosynthesis led to a depletion of intracellular cholesterol and an activation of the SREBP-cleavage activating protein (SCAP) conjugated sterol regulatory element binding protein (SREBP) transport activity, thereby resulted in up-regulation of LDLR and subsequent decrease of LDL-ch in blood. [23] [24] [25] In our study, plasma LDL-ch levels, but not cholesterol levels, were significantly down-modulated by CYP51-RNAi in hepatic cells. Based on previous studies, the data suggested that inhibition of cholesterol biosynthesis through silencing CYP51 gene may increase serum LDL-ch absorption by reducing endogenous cholesterol production of liver cells.
Because CYP51-siRNAs mainly decreased CYP51 expression and up-regulated LDLR levels in liver, liver might accumulate excess cholesterol to become a fatty liver. Our results showed that the extension of fatty hepatocytes in mice livers with the siRNA treatment was not greater than Buffer-group, which suggested that the siRNA action did not result in any fatty liver forming. In addition, we found that female mice ovulation was unaffected by CYP51-siRNAs treatment.
A serial studies show that CYP51 is proved to be critical in the feedback regulation of cholesterol reproduction. 26) In hypercholesterolemia pigs, SREBP-2 and CYP51 mRNA levels are decreased in the arterial wall cells. 27) In rat, the CYP51 levels were reduced by 3% cholesterol feeding. 28) Our data also suggested that HFHC diet down-regulated CYP51 expression of mouse hepatic cells. Notably, in normal mice, 5 mg/kg/d simvastatin resulted in a nearly 2-times CYP51 mRNA increasing, which was in line with those in rat, 29) whereas simvastatin did not significantly elevate CYP51 expression in HFHC mice. Such inconsistence may be that HFHC diet could down-regulate CYP51 expression for 20 d feeding period. 29) A feedback regulation of hepatic HMGCR by CYP51 is supposed to control cholesterol levels in liver. 29) Previous reports suggested that cholesterol, 28, 29) LDL-ch 27) or oxysterol 30) acted to first reduce the rate of transcription of CYP51 resulting in decreased the mRNA and protein levels and accumulation of the aldehyde intermediate, 3b-hydroxyl anost-8-en-32-al, which in turn acted to decrease translation of HMGCR mRNA. 31) 25-Hydroxycholesterol promotes the degradation of HMGCR 32) and suppresses the endoplasmic reticulum (ER)-to-Golgi transport of SREBP that are activating synthesis of cholesterol and other lipids. 33) Song et al. showed that lanosterol could be the potential stimulator for ubiquitination of HMGCR through insig protein pathway in ER. 34) Therefore, inhibition of CYP51 may cause loss of oxysterols or cholesterol and accumulation of lanosterol that could regulate, either directly or indirectly, other genes responded to lipid metabolism besides LDLR, which could contribute to circular LDL-ch levels reduction synthetically. Combined with our results, it is implicated that there was a cooperative relationship between CYP51 and HMGCR in modulating cholesterol levels.
CYP51 expression was down-regulated by the two weekfeeding of the HFHC diet, which is a disadvantage to treat CYP51 as an ideal target for RNAi. However, using RNAi to study the mechanism of CYP51-modulation of serum cholesterol homeostasis was superior to those nonspecific drugs because it is difficult to get the high specific inhibitor aiming at CYP51 at present. Although HFHC diet down-regulated CYP51 expression in liver, based on this case, CYP-1 significantly knocked down CYP51 mRNA and protein levels compared with day 0-, Buffer-and CYP-mis-group fed on HFHC diet as well.
The serum LDL levels of CYP-mis-and Buffer-group were greater than that in day 0 -group, but the mRNA levels of LDLR were hardly altered in these groups, which may be attributed to continuous HFHC diet caused serum cholesterol accumulation during 6 d feeding.
Although achieving in vivo gene silencing by RNAi encounters the main obstacle of delivery for clinical usage, liver genes are proved to be easily targeted through tail vein injection of the siRNAs. 35) 5-50 mg of synthesized EGFP-siRNAs resulted in a dose-dependent reduction of transgenic mice EGFP expression in a large percentage of hepatocytes at 48 h after systemic administration. 21) In our study, around 60% of CYP51 mRNA levels were knocked down when a single administration of 10 mg of in vitro transcribed CYP51-siRNAs. Moreover, if a sequential siRNAs (20 mg on day 0 and 10 mg on day 3) were injected in our designed models, as much as 50% (normal mice) to 70% (HFHC mice) mRNA and over 40% protein of CYP51 expression could be degraded. Taken together, the present data indicated that the siRNAs can specifically inhibit the expression of endogenous gene in adult mouse liver. The remaining problem is the effective and safe delivery method for introducing siRNAs into mammalian body for pharmaceutical use. Recently delivering chemically modified siRNAs into mammalian body was also proved to knock down target genes. 36, 37) Such modified siRNAs have plausible properties compared with traditional ones, such as more stable in sera, easier to be absorbed by cells and more powerful in action. The safety profiles of statins and siRNAs are very different. The toxicities at high doses with formulated siRNAs are mainly caused by the After RNAi treatment (20 mg CYP51-siRNAs in each mouse), each mouse was primed 5 IU of equine chorionic gonadotropin (eCG) and after 48 h, 5 IU of human chorionic gonadotropin (hCG) was primed each mouse. After 12-14 h, expanded COCs were recovered from oviducts and oocyte number was recorded. Oocyte number was counted from 12 mice in each treatment. The groups were not significantly different (pϾ0.05). lipid formulation. 18, 19) The safety of this siRNA treatment still needs more thorough investigation. In our study, CYP51-siRNA treatment did not lead to a fatty liver compared with Buffer group.
In conclusion, these data demonstrated that the siRNAs silenced CYP51 in mouse liver and down-regulated plasma LDL-ch levels. The potential mechanism of reduced LDL-ch may be related to up-regulated LDLR expression of liver cells. It indicated a link-modulated plasma cholesterol levels between cholesterol synthetic pathway through CYP51 and cholesterol transport pathway through LDLR in vivo.
